Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants.
Hizentra® is a 20% liquid IgG product approved for subcutaneous administration in adults and children greater than 2 years of age. We report two infants less than 2 years in which administration of Hizentra® was safe and effective.
Department of Pediatrics, Carolinas Medical Center, Levine Children's Hospital, Charlotte, NC 28232, USA.
Joel L
JL
Gallagher
Niraj C
NC
Patel
D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007223:Infant; D007279:Injections, Subcutaneous; D056770:Netherton Syndrome / Q000628:therapy*; D014424:Turner Syndrome / Q000628:therapy*
C558471:Hizentra; D007074:Immunoglobulin G